Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: A data analysis

Clinical Therapeutics

Volumn 28, Issue 7, 2006, Pages 1035-1040

  Frei, Christopher R ^a,b   Hampton, Shanna L ^a   Burgess, David S ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

lactams; culture site; Monte Carlo simulation; pharmacokinetics pharmacodynamics

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG BLOOD LEVEL; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; LUNG; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PSEUDOMONAS AERUGINOSA; STATISTICAL SIGNIFICANCE; VOLUNTEER; WOUND;

ADOLESCENT; ADULT; AGED; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; LACTONES; MALE; MIDDLE AGED; MOLAR, THIRD; PAIN, POSTOPERATIVE; SULFONAMIDES; SULFONES; TOOTH EXTRACTION;

EID: 33748682158     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.07.004     Document Type: Article

References (16)

1. Sorgel F., and Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31 Suppl A (1993) 39-60
2. White R. What in vitro models of infection can and cannot do. Pharmacotherapy 21 (2001) 292S-301S
3. Ambrose P., and Grasela D. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinoline pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 38 (2000) 151-157
4. Kuti J., Florea N., Nightingale C., and Nicolau D. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa. Pharmacotherapy 24 (2004) 8-15
5. Frei C., and Burgess D. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy 25 (2005) 1161-1167
6. Itokazu G., Quinn J., Bell-Dixon C., et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program. Clin Infect Dis. 23 (1996) 779-784
7. Neuhauser M., Weinstein R., Rydman R., et al. Antibiotic resistance among gram-negative bacilli in US intensive care untis: Implications for fluoroquinolone use. JAMA 289 (2003) 885-888
8. Approved standard M7-A6. CLSI/NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (2003), NCCLS, Wayne, Pa
9. Burgess D., and Frei C. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 56 (2005) 893-898
10. Kuti J., Nightingale C., and Nicolau D. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470
11. Occhipinti D., Pendland S., Schoonover L., et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 41 (1997) 2511-2517
12. Turnidge J. The pharmacodynamics of beta-lactams. Clin Infect Dis 27 (1998) 10-22
13. Craig W. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26 (1998) 1-10
14. Drusano G. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 36 Suppl 1 (2003) S42-S50
15. Moczygemba L., Frei C., and Burgess D. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin ther 26 (2004) 1800-1807
16. Thomson K., and Moland E. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 45 (2001) 3548-3554